Technology Appraisals Endorsement Process
The Department has reviewed its process for the endorsement, implementation, monitoring and assurance of NICE Technology Appraisals in Northern Ireland. The new arrangements are detailed in following circulars, which is effective from 18th December 2013;
NICE Technology Appraisals – Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 02/13.
For information, details of the previous arrangement can be found on the following circular;
NICE Technology Appraisals and Clinical Guidelines – New Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 04/11
2018/2019
The following technology appraisals have been endorsed during 2017/18. Information on technology appraisals endorsed in previous years can be found on the homepage.
Fully Endorsed
March 2019
NICE TA 540 - Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma
NICE TA 553 - Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence - Note this guidance has been updated and replaced by TA766 - Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma, which was endorsed by the DoH in February
NICE TA 557 - Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer - Note this guidance has been updated and replaced by TA683 - Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer, which was endorsed by the DoH in April 2021.
NICE TA 558 - Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease - Note this guidance has been updated and replaced by TA684 - Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease, which was endorsed by the DoH in April 2021.
NICE TA 561 - Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
February 2019
NICE TA 487 - Venetoclax for treating chronic lymphocytic leukaemia
‘Note this guidance has been updated and replaced by TA796 - Venetoclax for treating chronic lymphocytic leukaemia, which was endorsed by the DoH in July 2022’
NICE TA 490 - Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy ‘Note this guidance has been updated and replaced by TA736 - Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy, which was endorsed by the DoH in November 2021.’
NICE TA 491 - Ibrutinib for treating Waldenstrom’s macroglobulinaemia
‘Note this guidance has been updated and replaced by TA795 - Ibrutinib for treating Waldenstrom’s macroglobulinaemia, which was endorsed by the DoH in July 2022’
NICE TA 492 - Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable - Note this guidance has been updated and replaced by TA739 - Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable, which was endorsed by the DoH in November 2021.
‘Note this guidance has been updated and replaced by TA870 - Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma, endorsed by the DoH in March 2023.’
NICE TA 510 - Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
‘Note this guidance has been updated and replaced by TA783 - Daratumumab monotherapy for treating relapsed and refractory multiple myeloma, which was endorsed by the DoH in May 2022’.
NICE TA 517 - Avelumab for treating metastatic Merkel cell carcinoma
- This update and replaces NICE TA 517 - Avelumab for treating meteatatic Merkel cell carcinoma, which was endorsed by the DoH in May 2018.
- Note this guidance has been partially updated and replaced by TA691 - Avelumab for untreated metastatic Merkel cell carcinoma, which was endorsed by the DoH in May 2021.
- Note this guidance has been updated and replaced by TA692 - Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy, which was endorsed by the DoH in May 2021
- Note this guidance has been updated and replaced by NICE Technology Appraisal TA674 - Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal)
NICE TA 529 - Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
January 2019
NICE TA 550 - Vandetanib for treating medullary thyroid cancer
NICE TA 551 - Lenvatinib for untreated advanced hepatocellular carcinoma
NICE TA 552 - Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia
- This guidance updates and replaces NICE Technology Appraisal TA514, which was endorsed by the DoH in April 2018.
NICE TA 556 - Darvadstrocel for treating complex perianal fistulas in Crohn’s disease
NICE TA 472 - Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab Note this guidance has been updated and replaced by TA629 - Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab, which was endorsed by the DoH in July 2020
NICE TA 483 - Nivolumab for previously treated squamous non-small-cell lung cancer Note this guidance has been updated and replaced by TA655 - Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy, which was endorsed by the DoH in November 2020.
‘Note this guidance has been updated and replaced by TA784 - Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer, which was endorsed by the DoH in May 2022’.
NICE TA 484 - Nivolumab for previously treated non-squamous non-small-cell lung cancer - Note this guidance has been updated and replaced by TA713 - Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy, which was endorsed by the DoH in August 2021
December 2018
NICE TA 547 - Tofacitinib for moderately to severely active ulcerative colitis
November 2018
NICE TA 545 - Gemtuzumab ozogamicin for untreated acute myeloid leukaemia
NICE TA 546 - Padeliporfin for untreated localised prostate cancer
October 2018
NICE TA 542 - Cabozantinib for untreated advanced renal cell carcinoma
September 2018
NICE TA 538 - Dinutuximab beta for treating neuroblastoma
NICE TA 537 - Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs
NICE TA 536 - Alectinib for untreated ALK-positive advanced non-small-cell lung cancer
August 2018
NICE TA 532 - Cenegermin for treating neurotrophic keratitis
NICE TA 533 - Ocrelizumab for treating relapsing–remitting multiple sclerosis
NICE TA 534 - Dupilumab for treating moderate to severe atopic dermatitis
June 2018
NICE TA 521 - Guselkumab for treating moderate to severe plaque psoriasis
NICE TA 523 - Midostaurin for untreated acute myeloid leukaemia
NICE TA 524 - Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (review of TA446)
- This guidance updates and replaces NICE Technology Appraisal TA446, which was endorsed by the DoH in July 2017.
May 2018
NICE TA 518 - Tocilizumab for treating giant cell arteritis
April 2018
NICE TA 511 - Brodalumab for treating moderate to severe plaque psoriasis
NICE TA 512 - Tivozanib for treating advanced renal cell carcinoma
NICE TA 513 - Obinutuzumab for untreated advanced follicular lymphoma
NICE TA 514 - Regorafenib for previously treated advanced hepatocellular carcinoma
- This guidance has been updated and replaced by TA555 - Regorafenib for previously treated advanced hepatocellular carcinoma, which was endorsed by the DoH in January 2019.
- This guidance updates and replaces NICE Technology Appraisal TA250, which was endorsed by the DoH in May 2012.
NICE TA 516 - Cabozantinib for treating medullary thyroid cancer